Pliant Therapeutics Inc PLRX Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Pyott David E I

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

26,573

Price:

--
Dec 30, 2020 (filed on Jan 04, 2021)

Insider Name:

Hull Hans

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-3,500

Price:

--
Dec 30, 2020 (filed on Jan 04, 2021)

Insider Name:

Hull Hans

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

3,500

Price:

$2.08
Dec 21, 2020 (filed on Dec 23, 2020)

Insider Name:

Cummings Keith Lamont

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-4,500

Price:

--
Dec 21, 2020 (filed on Dec 23, 2020)

Insider Name:

Cummings Keith Lamont

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

4,500

Price:

$2.08
Dec 18, 2020 (filed on Dec 21, 2020)

Insider Name:

Lefebvre Eric

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-5,712

Price:

$26.98
Dec 18, 2020 (filed on Dec 21, 2020)

Insider Name:

Lefebvre Eric

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-6,788

Price:

$26.17
Dec 14, 2020 (filed on Dec 16, 2020)

Insider Name:

Coulie Bernard

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-337

Price:

$27.86
Dec 14, 2020 (filed on Dec 16, 2020)

Insider Name:

Coulie Bernard

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-3,163

Price:

$27.32
Dec 01, 2020 (filed on Dec 02, 2020)

Insider Name:

Cummings Keith Lamont

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-7,143

Price:

--

Filings by filing date

Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Pyott David E I

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

26,573

Price:

--
Dec 30, 2020 (filed on Jan 04, 2021)

Insider Name:

Hull Hans

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-3,500

Price:

--
Dec 30, 2020 (filed on Jan 04, 2021)

Insider Name:

Hull Hans

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

3,500

Price:

$2.08
Dec 21, 2020 (filed on Dec 23, 2020)

Insider Name:

Cummings Keith Lamont

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-4,500

Price:

--
Dec 21, 2020 (filed on Dec 23, 2020)

Insider Name:

Cummings Keith Lamont

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

4,500

Price:

$2.08
Dec 18, 2020 (filed on Dec 21, 2020)

Insider Name:

Lefebvre Eric

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-5,712

Price:

$26.98
Dec 18, 2020 (filed on Dec 21, 2020)

Insider Name:

Lefebvre Eric

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-6,788

Price:

$26.17
Dec 14, 2020 (filed on Dec 16, 2020)

Insider Name:

Coulie Bernard

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-337

Price:

$27.86
Dec 14, 2020 (filed on Dec 16, 2020)

Insider Name:

Coulie Bernard

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-3,163

Price:

$27.32
Dec 01, 2020 (filed on Dec 02, 2020)

Insider Name:

Cummings Keith Lamont

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-7,143

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Pharmaceuticals

See Regulatory Filings on SEC

Company Contact

Address:	260 Littlefield Avenue, Suite 150 SOUTH SAN FRANCISCO CA 94080
Tel:	1-650-4816770
Website:	https://pliantrx.com
IR:	See website

Key People

Bernard J. Coulie President, Chief Executive Officer, Director	Keith Cummings Chief Financial Officer	Barbara Howes Chief Human Resource Officer
Mike Ouimette General Counsel, Corporate Secretary	Hans P. Hull Chief Business Officer	Eric Lefebvre Chief Medical Officer

Business Overview

Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on discovering and developing therapies for the treatment of fibrosis. It focuses in treating fibrosis by inhibiting integrin-mediated activation of transforming growth factor beta (TGF-�). Its lead product candidate, PLN-74809, is an oral small-molecule, dual-selective inhibitor of av�6 and av�1. The Company's second clinical-stage product candidate, PLN-1474, is a small-molecule, selective inhibitor of av�1 in development for treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition to its clinical programs, it is developing additional preclinical integrin-based programs. The first preclinical program is oncology program. Its second preclinical program is an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor being developed for treatment of muscular dystrophies, including duchenne muscular dystrophy.

Financial Overview

For the nine months ended 30 September 2020, PliantTherapeutics Inc revenues totaled $37.4M. Net loss totaledto $22.5M.

Employees:	62 as of Dec 31, 2019

Reporting Currency:	U.S. Dollars
Enterprise value:	$624.22M as of Sep 30, 2020
Annual revenue (TTM):	N/A
EBITDA (TTM):	N/A
Net annual income (TTM):	N/A
Free cash flow (TTM):	N/A
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	35,479,853 as of Nov 7, 2020
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

INK Ultra Money Free

INK Ultra Money Videos

Pliant Therapeutics Inc (OQ:PLRX)